nitroaspirin has been researched along with mocetinostat in 4 studies
| Studies (nitroaspirin) | Trials (nitroaspirin) | Recent Studies (post-2010) (nitroaspirin) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 127 | 9 | 8 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | nitroaspirin (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, E; Cirino, G; Coata, G; Distrutti, E; Federici, B; Fiorucci, S; Morelli, A; Morelli, O; Renzo, GD; Santucci, L; Soldato, PD | 1 |
| Bernareggi, M; Berti, F; Berti, M; Colonna, VD; Del Soldato, P; Rossoni, G | 1 |
| Bernareggi, M; Berti, F; Colonna, VD; Manfredi, B; Rossoni, G | 1 |
| del Soldato, P; Dicay, M; Fiorucci, S; McKnight, W; Mencarelli, A; Wallace, JL; Zamuner, SR | 1 |
4 other study(ies) available for nitroaspirin and mocetinostat
| Article | Year |
|---|---|
Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase Inhibitors; Cell Line; Cysteine Proteinase Inhibitors; DNA Fragmentation; Endothelium, Vascular; Flurbiprofen; Gastric Mucosa; Humans; In Situ Nick-End Labeling; Male; Mice; Naproxen; Nitric Oxide; Peroxidase; Rats; Rats, Wistar | 1999 |
Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Aspirin; Creatine Kinase; Dose-Response Relationship, Drug; Electrocardiography; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Peroxidase; Rabbits; Vasoconstrictor Agents; Ventricular Function, Left | 2000 |
The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Creatine Kinase; Cyclic GMP; Fibrinolytic Agents; Hemodynamics; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; NG-Nitroarginine Methyl Ester; Peroxidase; Platelet Aggregation Inhibitors; Rats; Rats, Wistar | 2001 |
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Drug Interactions; Gastric Mucosa; Gastritis; Isoenzymes; Lipoxins; Male; Neutropenia; Neutrophil Infiltration; Nitric Oxide; Peroxidase; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction | 2004 |